Comparison of two immunization schedules with an inactivated hepatitis A vaccine (Avaxim(TM))

Journal of Travel Medicine

Volumn 5, Issue 4, 1998, Pages 167-172

  Vidor, Emmanuel ^a,c   Ratheau, Christine ^b   Briantais, Philippe ^a   Vuillier, Delphine ^a  

^a Pasteur Merieux Connaught   (France)

^b CENTRE HOSPITALIER DE VERSAILLES   (France)

^c Pasteur Merieux Connaught   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; ASTHENIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHEMA; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOMA; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; INJECTION PAIN; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VACCINATION;

EID: 0031798316     PISSN: 11951982     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1708-8305.1998.tb00501.x     Document Type: Article

References (24)

1. Vidor E, Fritzell B, Plotkin S. Clinical development of a new inactivated hepatitis A vaccine. Infection 1996; 24:447-458.
2. Lea AP, Balfour JA. Virosomal hepatitis A vaccine (Strain RG-SB). BioDrugs 1997; 7:232-248.
3. Nalin DR. VAQTA. Drugs of the Future 1995; 20:24-29.
4. Clemens R, Safary A, Hepburn A, et al. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995; 171(Suppl 1):S44-S49.
5. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992; 327:453-457.
6. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. J Am Med Assoc 1994; 271:1328-1334.
7. Prikazsky V, Olear V, Cernoch A, et al. Interruption of an outbreak of hepatitis A in two villages by vaccination. J Med Virol 1994; 44:457-459.
8. McMahon BJ, Beller M, Williams J, et al. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med 1996; 150:733-739.
9. van Damme P, Thoelen S, Cramm M, et al. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence. J Med Virol 1994; 44:446-451.
10. Wiens DL, Bohidar NR, Pigeon JG, et al. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol 1996; 49:235-241.
11. Totos G, Gizaris V, Papaevangelou G. Hepatitis A vaccine: persistence of antibodies 5 years after the first vaccination. Vaccine 1997; 15:1252-1253.
12. Maiwald H, Jilg W, Bock HL, et al. Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine. Vaccine 1997; 15:346-348.
13. Wiedermann G, Kundi M, Ambrosch F, et al. Inactivated hepatitis A vaccine: long term antibody persistence. Vaccine 1997; 15:612-615.
14. Wiedermann G, Ambrosch F, André FE, et al. Persistence of vaccine-induced antibody to hepatitis A virus. Vaccine 1992; 10(Suppl):S129-S131.
15. Goilav C, Zuckerman J, Lafrenz M, et al. Persistence of antibodies after inactivated hepatitis A vaccines in a comparative study. J Infect 1997; 34:158.
16. Berger R, Just M. Vaccination against hepatitis A: control 3 years after the first vaccination. Vaccine 1992; 10:295.
17. van Damme P, Thoelen S, Cramm M, Meheus A. Safety and immunogenicity of a high-potency inactivated hepatitis A vaccine. J Travel Med 1996; 3:83-90.
18. Holzer DR, Hatz C, Schmidt-Sissolak D, et al. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine 1996; 14:982-986.
19. Loutan L, Bovier P, Althaus B, Gluck R. Inactivated virosome hepatitis-A vaccine. Lancet 1994; 343:322-324.
20. Poovorawan Y, Theamboonlers A, Chumdermpadetsuk S, et al. Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais. Vaccine 1995; 13:891-893.
21. Frosner GG, Overby LR, Flehmig B, et al. Serological investigation of patients and family contacts in an epidemic of hepatitis A. J Med Virol 1977; 1:163-173.
22. Miller WJ, Clark W, Hurni WM, et al. Sensitive assays for hepatitis-A antibodies. J Med Virol 1993; 41:201-204.
23. Schmidtke P, Habermehl P, Knuf M, et al. Kinetics of hepatitis A virus (HAV)-specific humoral and cell mediated immunity after vaccination. Abstract 586, Infectious Diseases Society of America meeting, San Fransisco, September 1997.
24. Chen XQ, Boland GJ, van Hattum J, de Gast GC. T cell response to HAV after hepatitis A vaccination. Hepatology 1997; (in press).